Change over period: —
NSE · SPARC
SUNPHA ADV
-31.5% from the 52-week high · +74.9% above the low
Sun Pharma Advanced Research Co. Ltd. is a bio-pharmaceutical company, which engages in the research and development of pharmaceuticals. The company is headquartered in Mumbai, Maharashtra and currently employs 407 full-time employees. The company went IPO on 2007-07-18. The firm is in the business of research and development (R&D) of pharmaceutical products to unmet medical needs in the areas of oncology, neurodegeneration and immunology. The firm develops New Chemical Entities (NCE), New Biological Entities and reformulated products. Its NCE includes SCC-138, SCO-088, SCO-120 and SCD-044. Its Novel Drug Delivery Systems (NDDS) include Wrap Matrix Technology, Lipexelle technology and TearAct Technology. Wrap Matrix technology is useful to develop controlled release tablets. The company has developed Elepsia XR using Wrap MatrixTM technology. Lipexelle technology for ophthalmic formulations. The company has also developed Xelpros, a BAK free latanoprost eye drop developed using Lipexelle technology. Xelpros is commercialized by its partner in the United States. The company has also developed PDP-716 eye drops for treatment of Glaucoma based on its TearAct technology.
The short version. SUNPHA ADV reported revenue of ₹30 crore for Sep 2026, up 275.0% from a year earlier. Net profit was ₹-24 crore. Return on equity was 116.0% in Mar 2026. Promoter holding was 65.67% in Sep 2026, up 0.00 points over 8 quarters.
1 · The price
How has the stock traded?
SUNPHA ADV trades 31.5% below its 52-week high and 74.9% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹30 cr.
883.8 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30 | 40 | 1853 | 8 | 8 | 10 | 27 | 15 |
| Net profit | -24 | -21 | 1761 | -80 | -76 | -52 | -60 | -80 |
| Net margin % | -81.2 | -52.0 | 95.0 | -951.7 | -965.0 | -538.1 | -221.3 | -533.3 |
| EPS (₹) | -0.75 | -0.64 | 54.27 | -2.48 | -2.34 | -1.6 | -1.85 | -2.45 |
Annual
| FY2026 | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | 1879 | 72 | 76 |
| Net profit | 1553 | -343 | -387 |
| Net margin % | 82.7 | -477.5 | -512.5 |
| EPS (₹) | 47.86 | -10.56 | -11.93 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 116.0% in Mar 2026; debt to equity is 0.42.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 116.0 | 158.0 | -307.9 | — |
| Return on capital % | 112.0 | 862.1 | -154.1 | — |
| EBITDA margin % | 84.5 | -436.9 | -354.8 | — |
| Net margin % | 82.2 | -465.9 | -368.7 | — |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Unchanged over 8 quarters.
Up 1.52 pts over 8 quarters.
Down 0.53 pts over 8 quarters.
+4 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 65.67 | 0.0 |
| FII | 2.23 | 1.45 | 1.47 | 1.76 | 2.04 | 2.04 | 3.9 | 3.75 | +1.52 |
| DII | 0.64 | 1.13 | 0.97 | 1.05 | 0.78 | 0.88 | 0.09 | 0.11 | -0.53 |
| Public | 31.46 | 31.75 | 31.88 | 31.52 | 31.51 | 31.41 | 30.33 | 30.48 | -0.98 |
Mutual fund holdings · Oct 2026
12 schemes hold this stock
8 the month before.
- SAMCO MULTI CAP FUND0.3% of NAV
- Motilal Oswal Nifty Microcap 250 Index Fund0.2% of NAV
- Motilal Oswal BSE Healthcare ETF0.1% of NAV
- Bandhan BSE Healthcare Index Fund0.1% of NAV
- Motilal Oswal BSE 1000 Index Fund0.01% of NAV
- Bandhan Nifty Total Market Index Fund0.01% of NAV
- Angel One Nifty Total Market ETF0.01% of NAV
- Groww Nifty Total Market Index Fund0.01% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for SUNPHA ADV are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about SUNPHA ADV
What is the SUNPHA ADV share price?
SUNPHA ADV (SPARC) last closed at ₹192.57, up 1.29% on the day. Its 52-week range is ₹108.71 to ₹277.57.
What is the market cap of SUNPHA ADV?
SUNPHA ADV has a market capitalisation of about ₹6,169 crore. Its price-to-earnings ratio is 3.8.
How are SUNPHA ADV's latest results?
SUNPHA ADV reported revenue of ₹30 crore for Sep 2026, up 275.0% from a year earlier. Net profit was ₹-24 crore. Return on equity was 116.0% in Mar 2026. Promoter holding was 65.67% in Sep 2026, up 0.00 points over 8 quarters.
Who owns SUNPHA ADV?
As of Sep 2026, shareholding was: Promoter 65.67%, FII 3.75%, DII 0.11%, Public 30.48%.
How many mutual funds hold SUNPHA ADV?
12 mutual fund schemes held SUNPHA ADV in October 2026. That compares with 8 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 16 Mar 2016 · Rights issue 5:116
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.